Association of maternal psoriasis and small for gestational age or preterm birth: a nationwide matched cohort study in 69 080 singleton infants
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Forlagets udgivne version, 1,14 MB, PDF-dokument
Background: Women with certain inflammatory diseases have an increased risk of giving birth to infants who are small for gestational age (SGA) or preterm birth (PTB), with maternal disease activity being the most important risk factor. However, previous studies investigating an association between psoriasis and SGA are scarce and have shown conflicting results. Aim: To investigate the association between maternal psoriasis and risk of SGA infants and PTB, respectively, both overall and stratified by psoriasis severity. Methods: This was a nationwide register-based matched cohort study of women with psoriasis matched 1 : 10 to women without psoriasis on age at delivery, body mass index and smoking status and with their first singleton infant born during the period 2004–2017. Odds ratio (OR) and 95% CI were calculated in conditional logistic regression models adjusted for known risk factors. Results: From 516 063 deliveries, we identified 6282 women with psoriasis and 62 798 matched women without psoriasis. The risk of SGA and PTB was similar in women with psoriasis and matched controls: adjusted OR (aOR) = 1.07 (95% CI 0.98–1.17) and aOR = 1.05 (95% CI 0.93–1.19), respectively. The risk of term SGA was increased in women with psoriasis (aOR 1.11; 95% CI 1.01–1.22) compared with matched controls. Conclusion: Maternal psoriasis was not associated with increased risk of SGA or PTB. Risk of term SGA was slightly increased in women with a history of psoriasis compared with matched controls, however; these infants are likely to be constitutionally small with no increased risk of perinatal morbidity and mortality.
|Tidsskrift||Clinical and Experimental Dermatology|
|Status||Udgivet - 2022|
This work was supported by a research grant from the Danish National Psoriasis Foundation. The Danish National Psoriasis Foundation was not involved in study design, no access to raw data and did not participate in data collection, analysis or writing of the manuscript.
CBJ has received research funding research from the Danish National Psoriasis Foundation; research funding from and attended advisory board meetings for UCB; honoraria as consultant and/or speaker from Galderma, Estee Lauder Companies and L'Oréal. With no relation to the work reported in this manuscript, AE has received research funding from Pfizer, Eli Lilly, Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis Co. Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol‐Myers Squibb and Janssen Pharmaceuticals. EJS has received research funding from Eli Lilly, Vertex Pharmaceuticals and Janssen. LS has been a paid speaker for AbbVie, Eli Lilly, Novartis, Sanofi and LEO Pharma, and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall and Sanofi. She has served as an investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Pfizer, Regeneron and LEO Pharma, and has received research and educational grants from Novartis, Sanofi, Janssen Cilag and LEO Pharma. SFT is or recently was a speaker and/or advisor for, and/or has received research funding from: AbbVie, AstraZeneca, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pierre Fabre, Roche, Sanofi and UCB.
© 2022 British Association of Dermatologists.